Askanase, A., O. Berkani, C. Cahuzac, P. Cornelisse, D. D'Cruz, K. C. Kalunian, J. T. Merrill, M. Pozzobon and S. Navarra (2022). Efficacy and Safety of Cenerimod in Patients with Moderate to Severe Systemic Lupus Erythematosus (SLE): A Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled, Dose-Finding Phase 2b Trial. ACR Convergence.
European Medicines Agency. (2015). "Guideline on clinical investigation of medicinal products for the treatment of systemic lupus erythematosus and lupus nephritis." Retrieved 09 May, 2024, from https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-systemic-lupus-erythematosus-and-lupus-nephritis_en.pdf.
Strasser, D. S., S. Froidevaux, V. Sippel, E. Gerossier, U. Grieder, G. M. Pierlot, A. Kieninger-Graefitsch, E. Vezzali, A. K. Stalder, B. Renault, J. Ryge, A. Hart, U. Mentzel, P. M. A. Groenen, M. P. Keller, M. Trendelenburg, M. M. Martinic and M. J. Murphy (2020). "Preclinical to clinical translation of cenerimod, a novel S1P(1) receptor modulator, in systemic lupus erythematosus." RMD Open 6(2).
*The sponsor of the named study is currently Idorsia Pharmaceuticals Ltd. As of March 18, 2024, Viatris entered into a global collaboration with Idorsia, which includes cenerimod, and the study sponsorship is expected to be transferred to Viatris during the course of 2024.
Cenerimod is an investigational drug currently undergoing Phase 3 clinical trials. It has not been approved for use in any country. Viatris and/or Idorsia does not make, and expressly disclaims, any representations or warranties of any kind, either express or implied (including, without limitation, any implied warranties of content or non-infringement) with regard to any such information disseminated through this program/presentation/poster, including its accuracy and/or completeness. The viewers assume all risk for use of the information and the content provided in this program/presentation/poster. In no event shall Viatris and/or Idorsia or any of its affiliates, directors, employees, officers, consultants and service providers be liable, directly or indirectly, for any damages of any kind or nature, including without limitation, direct, indirect, incidental, consequential, or any claims or losses, whether foreseeable or not; whether or not the user has been informed of the possibility in advance; and whether or not resulting from or in connection with the creation or use of or reliance upon the program/presentation/poster.
Viatris Middle East FZ-LLC, Atlas Business Center, Floor 6, Al Falak Street, Dubai Media City, Dubai, United Arab Emirates, 502049
© 2024 Viatris Inc. All Rights Reserved.
VIATRIS and the Viatris Logo are trademarks of Mylan Inc., a Viatris company.